Drug Interactions Between Buspar, Melatonin, Ativan, and Benadryl
Combining buspirone (Buspar), lorazepam (Ativan), diphenhydramine (Benadryl), and melatonin creates significant risks due to additive CNS depression and should be avoided or used with extreme caution, particularly in older adults.
Primary Concern: Additive CNS Depression
The most critical interaction involves combining three or more CNS-active agents, which the 2019 AGS Beers Criteria explicitly warns against due to increased fall risk 1. Your combination includes:
- Lorazepam (benzodiazepine - CNS depressant)
- Diphenhydramine (antihistamine - CNS depressant)
- Buspirone (anxiolytic - mild CNS effects)
- Melatonin (sleep aid - sedating)
This four-drug combination substantially increases risks of:
- Falls and fractures
- Excessive sedation
- Cognitive impairment
- Respiratory depression
- Delirium (especially in older adults)
Specific Drug-Drug Interactions
Buspirone + Lorazepam
The FDA label states that buspirone coadministration with benzodiazepines like triazolam or flurazepam "did not appear to prolong or intensify sedative effects" 2. However, this does not mean the combination is safe—it simply means buspirone doesn't dramatically worsen benzodiazepine sedation. The concomitant use of buspirone with other CNS-active drugs "should be approached with caution" 2.
Lorazepam + Diphenhydramine
This specific combination has been studied and shows additive sedative effects 3. While the combination was used therapeutically in some contexts, it produced more sedation, less recall, and transient enuresis compared to either agent alone 4. The combination increases anticholinergic burden and sedation risk.
Diphenhydramine for Insomnia
Diphenhydramine is NOT recommended for treating insomnia according to the 2017 American Academy of Sleep Medicine guidelines 5. It showed minimal benefit (only 12 minutes improvement in total sleep time) with no improvement in sleep quality compared to placebo. Despite recent expert consensus suggesting it may be useful for acute insomnia 6, the higher-quality AASM guideline takes precedence.
Melatonin Interactions
Melatonin is primarily metabolized by CYP1A2, not CYP3A4 7. Melatonin has minimal pharmacokinetic interactions with the other three drugs in your combination. However, it adds to the overall sedative burden. The AASM also does NOT recommend melatonin for insomnia treatment (only 9 minutes reduction in sleep latency) 5.
Critical Warnings for Older Adults
If this combination is being considered for an older adult, the risks are substantially higher 1:
- Benzodiazepines (lorazepam) are potentially inappropriate in older adults
- Diphenhydramine has strong anticholinergic properties causing confusion, constipation, urinary retention
- Multiple CNS agents dramatically increase fall risk
Clinical Recommendations
If treating anxiety and insomnia together:
First-line approach: Use cognitive behavioral therapy for insomnia (CBT-I) with a single anxiolytic if needed 8
If pharmacotherapy is necessary:
- Choose ONE agent, not multiple
- For anxiety: Buspirone alone (non-sedating, no dependence risk)
- For insomnia: Consider orexin receptor antagonists (daridorexant) or eszopiclone over this combination 8
If already on this combination:
- Taper gradually (10-25% weekly dose reduction for benzodiazepines) 8
- Discontinue diphenhydramine first (can stop abruptly after short-term use)
- Discontinue melatonin (can stop abruptly)
- Taper lorazepam slowly to avoid withdrawal
- Continue buspirone if needed for anxiety
Monitor closely for:
- Excessive daytime sedation
- Falls or near-falls
- Cognitive changes or confusion
- Respiratory depression
- Paradoxical agitation
Common Pitfalls to Avoid
- Don't assume "natural" means safe: Melatonin still adds to sedative burden
- Don't combine multiple sedatives for insomnia: More drugs ≠ better sleep
- Don't use this combination long-term: Risk of dependence (lorazepam) and tolerance (diphenhydramine)
- Don't ignore anticholinergic burden: Diphenhydramine + other anticholinergics = delirium risk
The safest approach is to use the minimum number of agents necessary, preferably one, with non-pharmacological interventions as the foundation of treatment.